You are here

Article info

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin’s lymphoma

Authors

  • Kathryn Lurain HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA PubMed articlesGoogle scholar articles
  • Ramya Ramaswami HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA PubMed articlesGoogle scholar articles
  • Ralph Mangusan HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA PubMed articlesGoogle scholar articles
  • Anaida Widell HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA PubMed articlesGoogle scholar articles
  • Irene Ekwede HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA PubMed articlesGoogle scholar articles
  • Jomy George Clinical Pharmacokinetics Research Lab, Clinical Center Pharmacy, National Institutes of Health, Bethesda, Maryland, USA PubMed articlesGoogle scholar articles
  • Richard Ambinder Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Martin Cheever Cancer Immunotherapy Trials Network, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA PubMed articlesGoogle scholar articles
  • James L Gulley Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA PubMed articlesGoogle scholar articles
  • Priscila H Goncalves HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA PubMed articlesGoogle scholar articles
  • Hao-Wei Wang Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA PubMed articlesGoogle scholar articles
  • Thomas S Uldrick HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USADivision of Global Oncology, Department of Medicine, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA PubMed articlesGoogle scholar articles
  • Robert Yarchoan HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA PubMed articlesGoogle scholar articles

Citation

Lurain K, Ramaswami R, Mangusan R, et al
Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin’s lymphoma
Journal for ImmunoTherapy of Cancer 2021;9:e002097. doi: 10.1136/jitc-2020-002097
Online issue publication 
January 26, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.